Matej
Oresic
InFLAMES Flagship
Professor, Turku Bioscience Centre
Ph.D.
Areas of expertise
Systems biology
bioinformatics
metabolomics
lipidomics
biophysics
systems medicine
computational biology
Biography
Professor Matej Orešič holds a PhD in biophysics from Cornell University. He is Professor of Medical Sciences with Specialization in Systems Medicine at School of Medical Sciences (Örebro University, Sweden), Group Leader in Systems Medicine at the Turku Bioscience Centre (University of Turku, Finland), and Guest Professor at the Oil Crops Research Institute Chinese Academy of Agricultural Sciences (Wuhan, PR China). His main research areas are metabolomics applications in biomedical research and integrative bioinformatics. He is particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities, with specific focus on obesity and diabetes and their co-morbidities. Dr. Orešič has also initiated the popular MZmine open source project, leading to popular software for metabolomics data processing. Previosuly, Dr. Orešič was principal investigator at Steno Diabetes Center (Gentofte, Denmark), research professor at VTT Technical Research Centre of Finland (Espoo, Finland), head of computational biology and modeling at Beyond Genomics, Inc. (Waltham/MA) and bioinformatician at LION Bioscience Research in Cambridge/MA. In 2016, Dr. Oresic received the Lifetime Honorary Fellow award from the Metabolomics Society.
Research
Our main research area is systems medicine, particularly metabolomics applications in biomedical research and related integrative bioinformatics. Specifically, we am particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities. Such in depth understanding of the metabolic phenotypes in health and disease is crucial if one is to implement personalized medicine. Dr. Orešič initiated the popular MZmine open source project, leading to popular software for metabolomics data processing.
Main ongoing projects:
Strategic Research Agreement, Juvenile Diabetes Research Foundation (9/2016-9/2018): Metabolomic and Proteomic markers staging progression to type 1 diabetes in autoantibody positive children – PI
Strategic Research Agreement, Juvenile Diabetes Research Foundation (9/2016-9/2018): Mother-infant interactions in relation to potential biomarkers of beta-cell autoimmunity and type 1 diabetes – PI
Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012-2017) - PI
Strategic Research Agreement, Juvenile Diabetes Research Foundation (Integrative multi-omic study of early progression to type 1 diabetes; 2014-2017) - PI
pHealth Programme, multi-PI collaborative project, Academy of Finland (Personalised medicine to predict and prevent Type 1 Diabetes; 9/2015-8/2019) – Co-PI
EU H2020 EPoS (Elucidating Pathways of Steatohepatitis) - Workpackage leader
EU FP7 METSY (Integrated neuroimaging and metabolic platform for characterisation of early psychosis and prediction of patient outcomes) - Coordinator
Publications
Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort (2017)
Translational Psychiatry
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Modeling strategies to study metabolic pathways in progression to type 1 diabetes - Challenges and opportunities (2016)
Archives of Biochemistry and Biophysics
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease (2016)
Journal of Hepatology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans (2016)
Journal of Hepatology
(O2 Muu julkaisu )
The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes (vol 17, pg 260, 2015) (2016)
Cell Host and Microbe
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (2016)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI) (2016)
Metabolism
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Bioanalytical techniques in nontargeted clinical lipidomics (2016)
Bioanalysis
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016)
Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Interaction between dietary lipids and gut microbiota regulates hepatic cholesterol metabolism (2016)
Journal of Lipid Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))